Regulation of matrix remodeling by peroxisome proliferator-activated receptor-γ: A novel link between metabolism and fibrogenesis

Jun Wei, Swati Bhattacharyya, Manu Jain, John Varga*

*Corresponding author for this work

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

The intractable process of fibrosis underlies the pathogenesis of systemic sclerosis (SSc) and other diseases, and in aggregate contributes to 45% of deaths worldwide. Because currently there is no effective anti-fibrotic therapy, a better understanding of the pathways and cellular differentiation programs underlying fibrosis are needed. Emerging evidence points to a fundamental role of the nuclear hormone receptor peroxisome proliferator activated receptor-γ (PPAR-γ) in modulating fibrogenesis. While PPAR-γ has long been known to be important in lipid metabolism and in glucose homeostasis, its role in regulating mesenchymal cell biology and its association with pathological fibrosis had not been appreciated until recently. This article highlights recent studies revealing a consistent association of fibrosis with aberrant PPAR-γ expression and activity in various forms of human fibrosis and in rodent models, and reviews studies linking genetic manipulation of the PPAR-γ pathway in rodents and fibrosis. We survey the broad range of anti-fibrotic activities associated with PPAR-γ and the underlying mechanisms. We also summarize the emerging data linking PPAR-γ dysfunction and pulmonary arterial hypertension (PAH), which together with fibrosis is responsible for the mortality in patients in SSc. Finally, we consider current and potential future strategies for targeting PPAR-γ activity or expression as a therapy for controlling fibrosis.

Original languageEnglish (US)
Pages (from-to)103-115
Number of pages13
JournalOpen Rheumatology Journal
Volume6
Issue number1
DOIs
StatePublished - Jul 23 2012

Fingerprint

Peroxisome Proliferator-Activated Receptors
Fibrosis
Systemic Scleroderma
Rodentia
Cytoplasmic and Nuclear Receptors
Lipid Metabolism
Pulmonary Hypertension
Cell Biology
Homeostasis
Glucose
Mortality
Therapeutics

Keywords

  • PPAR-γ
  • SPPARM
  • Systemic sclerosis
  • TGF-β

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{e292d6a0557b41f19698ab216cc055b0,
title = "Regulation of matrix remodeling by peroxisome proliferator-activated receptor-γ: A novel link between metabolism and fibrogenesis",
abstract = "The intractable process of fibrosis underlies the pathogenesis of systemic sclerosis (SSc) and other diseases, and in aggregate contributes to 45{\%} of deaths worldwide. Because currently there is no effective anti-fibrotic therapy, a better understanding of the pathways and cellular differentiation programs underlying fibrosis are needed. Emerging evidence points to a fundamental role of the nuclear hormone receptor peroxisome proliferator activated receptor-γ (PPAR-γ) in modulating fibrogenesis. While PPAR-γ has long been known to be important in lipid metabolism and in glucose homeostasis, its role in regulating mesenchymal cell biology and its association with pathological fibrosis had not been appreciated until recently. This article highlights recent studies revealing a consistent association of fibrosis with aberrant PPAR-γ expression and activity in various forms of human fibrosis and in rodent models, and reviews studies linking genetic manipulation of the PPAR-γ pathway in rodents and fibrosis. We survey the broad range of anti-fibrotic activities associated with PPAR-γ and the underlying mechanisms. We also summarize the emerging data linking PPAR-γ dysfunction and pulmonary arterial hypertension (PAH), which together with fibrosis is responsible for the mortality in patients in SSc. Finally, we consider current and potential future strategies for targeting PPAR-γ activity or expression as a therapy for controlling fibrosis.",
keywords = "PPAR-γ, SPPARM, Systemic sclerosis, TGF-β",
author = "Jun Wei and Swati Bhattacharyya and Manu Jain and John Varga",
year = "2012",
month = "7",
day = "23",
doi = "10.2174/1874312901206010103",
language = "English (US)",
volume = "6",
pages = "103--115",
journal = "Open Rheumatology Journal",
issn = "1874-3129",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Regulation of matrix remodeling by peroxisome proliferator-activated receptor-γ

T2 - A novel link between metabolism and fibrogenesis

AU - Wei, Jun

AU - Bhattacharyya, Swati

AU - Jain, Manu

AU - Varga, John

PY - 2012/7/23

Y1 - 2012/7/23

N2 - The intractable process of fibrosis underlies the pathogenesis of systemic sclerosis (SSc) and other diseases, and in aggregate contributes to 45% of deaths worldwide. Because currently there is no effective anti-fibrotic therapy, a better understanding of the pathways and cellular differentiation programs underlying fibrosis are needed. Emerging evidence points to a fundamental role of the nuclear hormone receptor peroxisome proliferator activated receptor-γ (PPAR-γ) in modulating fibrogenesis. While PPAR-γ has long been known to be important in lipid metabolism and in glucose homeostasis, its role in regulating mesenchymal cell biology and its association with pathological fibrosis had not been appreciated until recently. This article highlights recent studies revealing a consistent association of fibrosis with aberrant PPAR-γ expression and activity in various forms of human fibrosis and in rodent models, and reviews studies linking genetic manipulation of the PPAR-γ pathway in rodents and fibrosis. We survey the broad range of anti-fibrotic activities associated with PPAR-γ and the underlying mechanisms. We also summarize the emerging data linking PPAR-γ dysfunction and pulmonary arterial hypertension (PAH), which together with fibrosis is responsible for the mortality in patients in SSc. Finally, we consider current and potential future strategies for targeting PPAR-γ activity or expression as a therapy for controlling fibrosis.

AB - The intractable process of fibrosis underlies the pathogenesis of systemic sclerosis (SSc) and other diseases, and in aggregate contributes to 45% of deaths worldwide. Because currently there is no effective anti-fibrotic therapy, a better understanding of the pathways and cellular differentiation programs underlying fibrosis are needed. Emerging evidence points to a fundamental role of the nuclear hormone receptor peroxisome proliferator activated receptor-γ (PPAR-γ) in modulating fibrogenesis. While PPAR-γ has long been known to be important in lipid metabolism and in glucose homeostasis, its role in regulating mesenchymal cell biology and its association with pathological fibrosis had not been appreciated until recently. This article highlights recent studies revealing a consistent association of fibrosis with aberrant PPAR-γ expression and activity in various forms of human fibrosis and in rodent models, and reviews studies linking genetic manipulation of the PPAR-γ pathway in rodents and fibrosis. We survey the broad range of anti-fibrotic activities associated with PPAR-γ and the underlying mechanisms. We also summarize the emerging data linking PPAR-γ dysfunction and pulmonary arterial hypertension (PAH), which together with fibrosis is responsible for the mortality in patients in SSc. Finally, we consider current and potential future strategies for targeting PPAR-γ activity or expression as a therapy for controlling fibrosis.

KW - PPAR-γ

KW - SPPARM

KW - Systemic sclerosis

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=84863946574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863946574&partnerID=8YFLogxK

U2 - 10.2174/1874312901206010103

DO - 10.2174/1874312901206010103

M3 - Review article

C2 - 22802908

AN - SCOPUS:84863946574

VL - 6

SP - 103

EP - 115

JO - Open Rheumatology Journal

JF - Open Rheumatology Journal

SN - 1874-3129

IS - 1

ER -